Breast cancer is one of the leading causes of mortality worldwide. Genomic studies have provided key insights into how breast cancer develop, evolve, metastasize, recurrence and respond to treatment. The advance of next-generation sequencing (NGS) and bioinformatics has led to an unprecedented view of the breast cancer genome and its evolution, and made the dynamic monitoring of recurrence and selective evolution of breast cancer during therapy a reality. Here we illustrate a proposed preclinical strategy of personalized and dynamic therapy for breast cancer based on the technologies of NGS and patient-derived tumor xenograft (PDX) model. The goal of this strategy is to provide a preclinical model of personalized and dynamic therapy for breast cancer to improve patients' outcomes.
INTRODUCTION INTRODUCTION
The breast cancer is the leading cause of cancer death in women with approximately 521,900 deaths per year worldwide (1) . It is predicted that there will be about 4292,000 newly diagnosed invasive cancer cases in 2015 in China (2) . The most commonly diagnosed cancer among women is breast cancer. It is expected to account for 15% of all new cancers in women (2) .
The patient-derived tumor xenograft (PDX) model retains similar growth and histopathological and molecular features compared with the original cancers. The unique feature of PDX models is that the implanted tumor tissue still retains most of its normal architecture and function (3, 4) . These characteristics make a PDX model an ideal method to predict tumor response to anticancer therapy including breast cancer (4-6) as well as to facilitate personalized cancer therapy.
nologies are now being applied to tumor DNA analysis to allow more comprehensive detection of mutations across wider genomic regions. Advances in NGS have made it possible to precisely characterize all somatic coding mutations that occur during the development and progression of individual cancers. The application of NGS together with advanced computational methods has provided technical support in selecting and monitoring therapy for breast cancer.
In this article, we illustrate a proposed preclinical strategy of personalized and dynamic therapy for breast cancer based on the technologies of PDX model and NGS to provide a preclinical model of personalized and dynamic therapy for breast cancer for improvement of patients' outcomes.
SELECTIVE EVOLUTION DURING CANCER SELECTIVE EVOLUTION DURING CANCER THERAPY THERAPY
Cancer is a disease characterized by Darwinian evolution (7, 8) . Clones evolve dynamically in space and time underpinning important emergent features such as metastasis, drug resistance and recurrence (9) (10) (11) (12) (13) (14) (15) . Advances in NGS and bioinformatics have led to an unprecedented view of the cancer genome and its evolution. An overwhelming body of evidence has been collected demonstrating that cancers evolve during progression and therapy (7, (16) (17) (18) (19) . Therapy represents a very defined and stringent selection pressure during the evolution of a cancer, and several studies have now traced the clonal evolution of tumors during the course of treatment (13, (20) (21) (22) (23) (24) . Selective evolution of cancer is likely to have important consequences in clinical practice and novel techniques to obtain representative samples for genetic analyses, especially from metastatic and recurrent disease, are urgently needed to understand the clonal dynamics of evolving tumors through course of disease and therapy.
TUMOR-SITE-BASED HETEROGENEITY TUMOR-SITE-BASED HETEROGENEITY OF SOLID TUMOR OF SOLID TUMOR
Numerous genomic studies have demonstrated intratumor heterogeneity and heterogeneity in primary tumors, corresponding metastatic and recurrent tumors as recognized characteristics of solid tumors (9) (10) (11) (12) (13) (14) (15) 21, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . These genomic differences may affect the clinical outcome of anticancer therapy. The results of a retrospective study gave us the direct evidence to reveal that the genetic heterogeneity in primary colorectal tumors and their corresponding metastases have different responses to EGFR-targeted therapy (39) .
Studies of glioma recurrences found that the driver mutation landscapes were often significantly different from the initially detected driver mutations, suggesting that clones initiating recurrences had branched off early in tumor evolutionary histories (21) . Morrissy AS, et al. demonstrated the heterogeneity between primary tumor and recurrent tumor (26) . These studies indicated that molecularly targeted therapy is unlikely to be effective when the target is absent in the metastatic or recurrent tumors. In certain contexts, continued therapy in absent of target might accelerate tumor progression (40) .
PATIENT-DERIVED TUMOR XENOGRAFT PATIENT-DERIVED TUMOR XENOGRAFT (PDX) MODEL FOR PERSONALIZED AND (PDX) MODEL FOR PERSONALIZED AND DYNAMIC THERAPY FOR BREAST CANCER DYNAMIC THERAPY FOR BREAST CANCER
The patient-derived tumor xenograft (PDX) model has a sound establishing method and a retained similarity to the corresponding original donor tumors in histologic presentation and biological behavior. The PDX model has the potential to be a candidate strategy for personalized cancer therapy. The results of a study led the investigators to conclude that the PDX model of first generation of non-small cell lung cancer (NSCLC) is suitable for quick assessment of the chemosensitivity of patients' cancers and selection of the most effective regimens. In this study, the first generation subrenal capsule xenografts of primary NSCLC were examined for determining responses to conventional chemotherapeutic regimens and selecting regimens most effective for individual patients (41) . In a large preclinical trial, the investigators established 1,075 PDX models from a range of human solid tumor samples and carried out a PDX clinical trial with 62 treatments. Their results correlated genomic alterations with responses to therapy, which confirmed the relationships that have already been established and thus validated the approach (6) .
The PDX models of primary and metastatic tumors have been established in our laboratory and have been used for antitumor drug sensitivity assays which could guide clinical practice of personalized cancer therapy (4, (42) (43) (44) (45) (46) (47) (48) . Based on our clinical and laboratorial experience, it is practical to obtain primary or metastatic breast cancer for PDX model use even if the spreading of the tumor is extensive.
NEXT-GENERATION SEQUENCING NEXT-GENERATION SEQUENCING
Recent advances in genomics technologies are now providing new opportunities for the analysis of tumor DNA. NGS technologies are now being applied to tumor DNA analysis to allow more comprehensive detection of mutations across wider genomic regions. Advances in NGS have made it possible to precisely characterize all somatic coding mutations that occur during the development and progression of individual cancers (10, 11, 14, 15, 26, 37, (49) (50) (51) (52) (53) (54) . Whole-genome sequencing (WGS) has now been directly applied to tumor DNA analysis, to provide an unprecedented view of somatic chromosomal alterations and copy number aberrations in tumor DNA genome-wide (10, 11, 14, 15, 26, 37, (49) (50) (51) (52) (53) (54) . NGS of tumor DNA could be an effective tool for monitoring tumor burden, evolution, therapeutic responses and resistance to therapy.
Monitoring tumor burden and treatment response is important in all phases of cancer management to avoid continuing ineffective therapies, to prevent unnecessary side-effects and to determine the benefit of new therapeutics. The technique of NGS facilitated the oncologists to investigate cancer to a new level, the dynamic genetic level.
HYPOTHESIS AND PERSPECTIVE HYPOTHESIS AND PERSPECTIVE
Given these advances and the scientific data mentioned above, here we hypothesize and illustrate a proposed preclinical strategy of personalized and dynamic therapy for breast cancer based on the technologies of NGS and PDX model ( fig. 1) . In this strategy, radical surgery will be firstly performed when a breast cancer is pathologically confirmed, following the dynamic therapy such as chemotherapy or chemotherapy in combination with molecularly targeted therapy based on the results from NGS using tumor DNA and imaging technologies such as CT, MRI or PET-CT. In this process, the tumor DNA from the resection of primary breast tumor and metastatic tumors such as brain metastasis, lung metastasis, and bone metastasis were sent for NGS analysis to obtain the drug sensitivity data for drug selection. And simultaneously, part of resected tumors was used for establishment of PDX model for therapy interference using the same drugs as the patient received. During the generation of PDX, the tumors were resected for monitor the selective evolution of tumor in selected time points to obtain the drug resistance data for termination of the current ineffective therapies and obtain the renewed drug sensitivity data to choose new effective drugs. These renewed drugs sensitivity data from PDX model could be used for drug selection when the metastases or recurrence of breast cancer occurred. The goal of this proposed preclinical strategy is to realize personalized and dynamic systemic therapy for cancer and improve patients' outcomes.
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